NCT03573960 2026-03-06
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Eisai Inc.
Phase 4 Completed
Clinical Trials
9 trialsNCT07160361 2025-09-16
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT06195228 2025-08-14
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Fudan University
Phase 4 Recruiting
NCT07010393 2025-06-08
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Fujian Medical University
Phase 4 Not yet recruiting
NCT06499610 2024-07-12
Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT06417606 2024-05-22
Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma
Tongji Hospital
Phase 4 Not yet recruiting
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT04297254 2023-11-15
A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
Eisai Inc.
Phase 4 Completed
NCT04127396 2021-07-23
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Beijing Ditan Hospital
Phase 4 Unknown